SAN DIEGO, July 8, 2025 ~ Circular Genomics, Inc. has received a significant investment of $250,000 from the Alzheimer's Drug Discovery Foundation (ADDF) through its Diagnostics Accelerator (DxA) program. This investment will support further research on Circular Genomics' circRNA blood-based biomarkers for diagnosing and predicting the progression of Alzheimer's disease (AD).

As a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, Circular Genomics is dedicated to developing the first blood-based tests that utilize circRNA to enable personalized diagnosis and treatment for complex neurological and psychiatric conditions, such as AD.

The investment, titled "Alzheimer's Disease Specificity and Sensitivity Analyses of circRNA Blood Markers," will fund research conducted in partnership with Carlos Cruchaga, PhD, Director of the NeuroGenomics and Informatics Center at Washington University of Medicine in St. Louis. The project aims to further study the potential of circRNA biomarkers to improve the diagnosis of AD and distinguish it from other dementias, providing clarity for patients and their healthcare providers.

More on S For Story

• Louisiana's First Dedicated Residential Eating Disorder Treatment Center for Women Opens Near New Orleans
• Post-Traditional Career Expert Sandra Buatti-Ramos Receives 2025 Top Career Coach Recognition
• CCHR Calls for Audit of Forced Psychiatric Drugging and Systemic Misdiagnosis
• St. Paul, Mn Goes Ninja: Emmy-winning Naruto Star Maile Flanagan Headlines Inaugural Anime Wonder Fest
• Local Author Heather Barbour Fenty Releases Third Book in Beloved "Sea Series"

"We are honored to receive this investment from the ADDF as we continue to advance our suite of circRNA-based tools aimed at addressing the need for reliable diagnosis and prognosis for neurological conditions such as Alzheimer's," said Nikolaos Mellios, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics. "Our goal is to transform the diagnostic and treatment journey for patients by enabling earlier detection, better patient stratification, and more personalized clinical management of the disease."

Dr. Cruchaga, a renowned expert in neurogenomics and biomarker discovery, also expressed excitement about this collaboration: "CircRNA biomarkers offer an exciting and promising approach for improving diagnostic accuracy and advancing personalized care for Alzheimer's. I'm looking forward to working with Circular Genomics to progress this innovative technology with the goal of improving outcomes for individuals at risk of AD through an earlier and more accurate diagnosis."

CircRNAs have been shown to play important roles in brain development, maturation, function, and aging, and have been linked to many neurological and psychiatric disorders. Their abnormal expression in pathological states makes them potential diagnostic and predictive biomarkers for numerous brain disorders. While circRNAs are mainly expressed in the brain, they can also be measured in blood, providing a window into overall brain health.

More on S For Story

• FDA Fast Track Designation for $3 Billion Suicidal Depression Market May Soon be Accessible for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals
• Slotozilla Expands Partner Network With 25+ Affiliates and Unveils 139 New Bonuses in Q2 2025
• Who the Hell is Cloud9 Network—And Why Is Everyone Suddenly Watching?
• Speaking Every Child's Language: The Data Detective Expands Globally with 5 Translations
• Newport Heights' Most Coveted Coastal Estate

The research funded by this investment will further quantify and characterize blood brain-derived circRNA biomarkers to create best-in-class tools for predicting AD's progression and enabling a more accurate diagnosis.

According to Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF, "Circular Genomics' work represents the type of innovative science needed to transform how we detect and diagnose Alzheimer's disease." He added that by investing in accessible and scalable biomarker technologies like this one, they aim to accelerate earlier and more accurate diagnosis, which is a critical step towards treating Alzheimer's with precision medicine.

The DxA program is a $100 million global research initiative aimed at fast-tracking the development of biomarkers and diagnostic tools for the detection and diagnosis of Alzheimer's disease and related dementias. This investment from ADDF will undoubtedly support Circular Genomics' mission to improve outcomes for individuals at risk of AD through earlier detection and personalized care.

---

Show All News | Report Violation